Condyloma eradication: self-therapy with 0.15-0.5% podophyllotoxin versus 20-25% podophyllin preparations--an integrated safety assessment.
Topical application of podophyllin solution, long considered the therapy of first choice against condylomata acuminata, can no longer be recommended due to its low efficacy and gross toxicity. Self-treatment with 0.15-0.5% purified podophyllotoxin preparations, applied twice daily for 3 days, is now advocated as the alternative first-line therapy of choice, when significant improvement is conveniently, and cost-effectively, accomplished within a few weeks. This review provides a summary of the comparative efficacy and utility of podophyllin versus podophyllotoxin as well as a compilation of in vivo and in vitro safety evaluations. In light of overwhelming safety and efficacy data in favor of podophyllotoxin-derived products, it is concluded that podophyllin preparations have no place in the modern treatment portfolio for anogenital warts.
Longstaff
E
E
Stiefel Laboratories R&D, Holtspur Lane, Wooburn Green, High Wycombe, Buckinghamshire, HP10 0AU, United Kingdom.
von Krogh
G
G
D000287:Administration, Topical; D000818:Animals; D002415:Cats; D002986:Clinical Trials as Topic; D003218:Condylomata Acuminata / Q000188:drug therapy* / Q000453:epidemiology; D019317:Evidence-Based Medicine; D006168:Guinea Pigs; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000633:toxicity*; D051379:Mice; D009152:Mutagenicity Tests; D011033:Podophyllin / Q000008:administration & dosage / Q000633:toxicity*; D011034:Podophyllotoxin / Q000008:administration & dosage / Q000633:toxicity*; D017410:Practice Guidelines as Topic; D011817:Rabbits; D051381:Rats; D012098:Reproduction / Q000187:drug effects; D018675:Toxicity Tests
D007641:Keratolytic Agents; D011033:Podophyllin; D011034:Podophyllotoxin